Subsequent use of breast cancer biomarkers in routine practice and molecular characterization of breast cancer confirmed different prognostic groups of ER+ breast cancers and heterogeneous benefit from cytotoxic chemotherapy [11, 12]. The gene discussed is ESR1; the disease is breast cancer.